Drug against shock


(57) Abstract:

Developed the drug against shock polydisulfide Gallic acid. The drug is more effective than used in practice contrical. table 1.

The invention relates to biology and medicine and relates to a medicinal product that protects from shock.

Known use as antishock drugs plasmaatomic solutions, promedol, droperidola, dopamine, and Talamone. But when the shock is observed when the drugs are administered in large enough doses and do not provide a high survival rate.

Closest to the invention on the effectiveness of actions is used as antishock drug kontrikala.

The problem to which the invention is directed, is the extension of the range of funds with antishock effect and higher efficiency compared to the prototype.

The problem is solved by the use as an anti-shock tool polydisulfide Gallic acid of the formula I


where n = 12 to 16.

Polydisulfide Gallic acid obtained by condensation of Gallic acid with odnomerno dried o-, m-, p-xylene and with vigorous stirring, 13.5 g (8.1 oz) odnoklasniki sulfur within 15 - 20 min, then heated the reaction mass at 110 - 120oC to complete the termination of allocation of hydrogen chloride. At the end of the reaction the precipitate of polysulfide Gallic acid is filtered off, washed with o-, m-, p-xylene and then with water until a negative reaction to chlorine ion. The synthesis time is 30 hours; exit 92 - 95%. TPL= 260 - 262oC with decomposition. A reaction scheme II:

< / BR>
Polydisulfide Gallic acid - substance light yellow color.

Found, wt.%: C 38,60; H 1,33; S 24,59.

Calculated, wt.%: C 36,21; H 1,72; S 27,59.

Mol. mass (cryoscopy in diphenyl) found 3600.

Infrared absorption spectrum ( cm-1): 480-S-S-,

870-C-H - pentamidine benzene;


1480-benzene ring;


3300-OH polymer.

Antishock effect of polydisulfide Gallic acid tested in the laboratory, experiments are performed on 40 rats "Wistar" weighing 200 - 250 g To simulate the shock applied by the imposition of a tight tourniquet on the hind limbs of rats for a period of 6 hours drug injected intraperitoneally immediately before the removal of the tourniquet.

Characteristics of drugs in the antishock efficiency are presented in table illustrating the status of the rats at various times after removal of the tourniquet.

It is established that the proposed tool increases their life expectancy by 20 - 30% compared with the action antishock drug-kontrikala, i.e. it has a more pronounced antishock effect compared to the prototype.

Polydisulfide Gallic acid by antishock action exceeds contrical and has an antioxidant effect (inhibits the oxidation of lipids) that can be used in conditions of experimental clinic for the correction of various pathological conditions involving shock body conditions of the animals, and with the permission of the pharmacological Committee in humans, particularly during ischemia associated with shock.

Drug against shock, characterized in that the submission


Same patents:

The invention relates to the oligoesters, method for their production and compositions on their basis, which possess significant activity against the virus of human immunodeficiency and is used for the treatment of acquired immunodeficiency syndrome (AIDS)

FIELD: medicine.

SUBSTANCE: method involves drying injured zone after having removed dental deposit and additional treating cement surface in inflammation zone with citric acid solution of 0.1 mMole/l concentration during 5 min, and then with 0.06% Chlorohexidine solution and Nikiforov mixture. Sulfacrylate is placed into periodontium pocket as glue periodontial bandage and the lesion focus is treated with ultrasound of 26.5 kHz during 3 s.

EFFECT: accelerated treatment course; activated reparative processes in periodontium; improved mechanical strength; accelerated polymerization in glue bandage.

2 tbl

FIELD: medicine.

SUBSTANCE: novel biomaterials consist of combination of sulphated hyaluronic acid and deacetylated hellane for application as highly efficient barrier for prevention of post-operation commissures in operation in abdominal, pelvic areas and, first of all, on spine.

EFFECT: increase of application efficiency.

16 cl, 1 dwg, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to high-molecular compounds for medical purposes. Water-soluble polymeric complexes of antiviral agent arbidol of general formula: are described, where: Arb - arbidol: ethyl ester 6-bromo-4-dimethyl-aminometil-1-methyl-5-oxy-2-feniltiometilindolinil-3-carboxylic acid hydrochloride monohydrate; m1=100-(m2+m3) mol %; m2=(7.6-9.8) mol %; m3=(11.5-13.6) mol %; content of Arb=26.4-32.1 wt %.

EFFECT: obtained water-soluble polymeric complexes of arbidol may find application in pharmacology, as they can serve as basis for new effective and safe antiviral drugs and their dosage forms.

1 cl, 6 ex, 4 tbl, 2 dwg

Transdermal plaster // 2445084

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly pharmaceutical preparations, namely: plasters for transdermal application. Substance of invention consists in the fact that a transdermal plaster representing a matrix system and comprising a lining layer, a matrix layer and a lightproof protective coating in the following proportions is produced: 6.72 wt % of hypoxene substance, 15.11 wt % of sodium metabisulphite in propylene glycol with 0.067% of sodium metabisulphite, as well as 56.0 wt % of 95% ethanol and 22.17 wt % of PVP K30. The plaster aims at the transdermal introduction of hypoxene. A plaster area is 25 cm2.

EFFECT: offered plaster used for treating and preventing chronic diseases allows avoiding the problems related to oral administration, improves patient compliance, enables prolonged maintenance of the hypoxene concentration; it is suitable for purposes of combination therapy.

6 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a group of inventions which refers to medicine, namely dermatology. The group of inventions involves the use of a known compound as an agent for preparing a composition for stimulating and/or accelerating fibroblast proliferation in vivo and ex vivo, and respectively wound healing, as a wound healing dressing containing such compound. This compound represents a copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propane sulfonic acid salt and propenoic acid 2-hydroxyethyl ester. It may be used either separately or in a combination with the other active substances for inducing or accelerating wound healing. This compound either separately, or in a combination with the other active substance may be introduced on the wound directly and a surrounding area or mucous membranes by local application. The presents inventions also find application for making dressings on the basis of hydrogels and hydrocolloids which contain said copolymer. For the purpose of the use in vivo, the given copolymer is used in the composition or in the dressing for wound healing that promotes better improvement of wound surface regeneration and healing stimulation.

EFFECT: use of the copolymer ex vivo is effective for autologous skin or skin-epidermal transplants as that enables accelerating fibroblast proliferation.

3 tbl

FIELD: pharmacology.

SUBSTANCE: invention relates to the high-molecular weight compounds of the medical purpose, more specifically to new synthetical sulfo-containing homo- and copolymers 2-acrylamido-2-methylpropansulfoacid with its own bioactivity that can be used in pharmacology in the capacity of the future-proof antiviral agents or can serve as the basis for the new effective and harmless antiviral medicinal agents and its pharmaceutical forms. The homo- and copolymers 2-acrylamido-2-methylpropansulfoacid of the stated below formula are obtained by the radical heterophase (co)polymerization in the ethanol at 70°C within 24 hours. The homo- and copolymers 2-acrylamido-2-methylpropansulfoacid have the molecular weight MM=(40-70)⋅103.



m=100 mol. %, n=0;


m=(22.8-58.1) mol. %, n=(77.2-41.9) mol. %.

EFFECT: invention allows to get nontoxical homo- and copolymer 2-acrylamido-2-methylpropansulfoacid with its own antiviral activity against the influenza viruses H3N2, H1N1.

1 tbl, 2 ex